Research

Micronutrients & recovery

Supplementation with 500 mg/day of resveratrol for 12 weeks significantly reduces serum alanine aminotransferase (ALT) and hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD) compared to placebo.

If you have NAFLD, taking 500 mg of resveratrol daily for 12 weeks may help lower liver enzymes (ALT) and reduce liver fat, but it will not fix your cholesterol, blood pressure, or insulin resistance. Do not rely on it as a substitute for a healthy diet and regular exercise.

GoodSupportsHIGH confidence
resveratrol supplementation reduced alanine aminotransferase (ALT) and hepatic steatosis significantly more than placebo (P < 0·05).
Forouzan Faghihzadeh et al. · British Journal Of Nutrition · 2015

Why this rating

Randomized, double-blind, placebo-controlled clinical trial with adequate blinding and high adherence, though sample size is modest (n=50).

Source

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

Forouzan Faghihzadeh et al. · British Journal Of Nutrition · 2015

rct · n=50Cited 185×
Read the paper

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →